18.68 +0.33 (1.80%)
Pre-market: 4:00AM EDT
|Bid||17.85 x 1000|
|Ask||19.00 x 1100|
|Day's range||17.74 - 18.75|
|52-week range||8.86 - 32.48|
|Beta (5Y monthly)||0.89|
|PE ratio (TTM)||N/A|
|Earnings date||23-Jun-2021 - 28-Jun-2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||18.75|
Rite Aid's (RAD) Q4 results gain from RxEvolution strategy, strength in Elixir brand and robust online growth. However, COVID-related costs woes and lesser cases of cough, cold and flu are concerns.
Rite Aid Corporation (NYSE: RAD) today reported operating results for its fourth quarter and fiscal year ended February 27, 2021.
Solid performance in PBM and Elixir along with expanded omnichannel services is expected to have aided Rite Aid's (RAD) Q4 revenues. However, COVID-19 woes remain concerns.